The Short-term Clinical Efficacy And Safety Of Paclitaxel Com Bind With Cisplatin By Hyperthermic Intraperitoneal Perfusin In The Treatment Of Gastric Cancer With Ascites

Objective:This thesis is to investigate the efficiency and safety of paclitaxel combind with cisplatin by hyperthermic intraperitoneal perfusin in the treatment of gastric cancer with ascites.Methods:A total of 75 patients of gastric cancer with ascites from May2014 to December 2016 were collected.According to the different treatment methods,the patients were divided into the observation group(n=40)and the control group(n=35).The two groups were treated with intravenous infusion of paclitaxel 175 mg/m2 for first days.Cisplatin D1 60mg,D5 60mg:the observation group was injected into the abdominal cavity by the thermostatic perfusion apparatus with constant temperature(43?),and the control group was injected into the abdominal cavity with normal saline 500 ml,3 week for 1 cycles.After 4-6cycles.The data of clinical treatment effect,serum carcinoembryonic antigen concentration,the quality of life and the complications of the two groups were statistically analyzed.1-year cumulative survival rates were compared between the two groups.Results:The effective rate of observation group was significantly higher than the control group(60.00%vs 37.14%,X~2=3.902,P=0.048).Though the serum CEA decrease after treatment by the two different therapeutic regimens(P<0.05),the decreases in the observation group were more significant than the control group(P<0.05).There were no significant difference in the 1-year cumulative survival rate and the Incidence of adverse reactions between the two groups after treatment.Conclusion:Intravenous infusion of paclitaxel combind with cisplatin by hyperthermic intraperitoneal perfusin in the treatment of gastric cancer with ascites has a better short-term clinical effect,because It can improve some patients'quality of life and may prolong the survival time of some patients,and the adverse drug reaction can be tolerated.